Beryl Drugs: Promoter Sudhir Sethi Acquires 800 Shares

Beryl Drugs Limited announced that its promoter and director, Sudhir Sethi, purchased 800 equity shares on March 20, 2026. This acquisition represents a 0.02% stake in the company, valued at approximately ₹16,640.

Promoter Transaction Details

Sudhir Sethi acquired 800 equity shares through an open market transaction on March 20, 2026. This purchase represents 0.02% of Beryl Drugs Limited's total outstanding shares. Following the acquisition, Mr. Sethi's holding increased to 4,78,983 shares. The transaction was valued at ₹16,640, indicating a per-share price of ₹20.8.

Why This Stake Buy Matters

For a small-cap company like Beryl Drugs, any stake increase by a promoter can draw investor attention and signal confidence in future prospects, even if the acquisition is small. This latest purchase suggests a degree of promoter commitment, though the minimal increase may indicate it is primarily a routine consolidation.

About Beryl Drugs and Sudhir Sethi

Beryl Drugs Limited, established in 1993 and based in Indore, manufactures pharmaceuticals including bulk drugs, formulations, I.V. fluids, and injectables, with bulk drugs being its main revenue driver. Sudhir Sethi is the Chairman and has served as a director since at least 2011, with a re-appointment in May 2022. Company filings show previous disclosures by Mr. Sethi on March 11 and 13, 2026, related to SEBI (Substantial Acquisition of Shares & Takeovers) Regulations.

Shareholding Structure

The acquisition has a minimal direct impact on existing shareholders' control or voting power. The overall shareholding structure remains largely unchanged, with promoters holding approximately 26.4% of the company and retail investors holding the majority.

Key Risks and Challenges

Beryl Drugs has faced challenges, including historically modest sales growth of 10.6% over five years and a low interest coverage ratio. An older auditor's report from 2011 flagged an overstatement of profit and investment due to a failure to account for diminished share value. The company operates as a small-cap entity, with a market capitalization significantly lower than its larger pharmaceutical peers.

Peer Comparison

Beryl Drugs' market capitalization of around ₹10.8 Crore stands in stark contrast to major pharmaceutical players. For example, Sun Pharma has a market cap of approximately ₹4.3 lakh crore, Divi's Laboratories around ₹1.6 lakh crore, Torrent Pharma around ₹1.45 lakh crore, and Zydus Lifesciences approximately ₹89,595 Crore as of March 2026.

Current Shareholding Breakdown

As of March 2026, promoter holding in Beryl Drugs was 26.38%, while retail investors held 73.62%. Foreign and Domestic Institutional Investors held 0%.